Home › NCT06428097

Levothyroxine Supplementation for Heart Transplant Recipients

Levothyroxine Supplementation for Heart Transplant Recipients: A Randomized Control Trial

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Participants must be listed for heart transplantation
2. Age ≥18 years
3. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Patients with pre-existing thyroid related condition including hypothyroidism, hyperthyroidism and malignancy
2. Patients with a known allergy or intolerance to levothyroxine
3. Patients participating in another study evaluating an investigational drug within the past 30 days.

About the study

This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.

What is being tested

• Levothyroxine (drug)
• Normal saline (drug)

Sponsor: University of California, San Francisco · Participants: 97 · Started: Mar 29, 2024

Contact the study team

• Corinne Dietz · Phone: 415-353-7083
• Lea Daran · Phone: 415-502-4320

Official record on ClinicalTrials.gov — NCT06428097

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.